Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.39 |
| ▸ | METAP2 | P50579 | 5/20 | 0.38 |
| ▸ | METAP1 | P53582 | 3/20 | 0.38 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7268749 | 0.84 | CTSK (0.39) | CPB2CTSSCTSKLTA4HREN | |
| SCHEMBL1859134 | 0.84 | CTSK (0.39) | CPB2CTSSCTSKLTA4HREN | |
| SCHEMBL3613229 | 0.84 | METAP2 (0.43) | CPB2METAP2METAP1SLC1A3SLC1A2 | |
| SCHEMBL4972480 | 0.84 | METAP2 (0.43) | CPB2METAP2METAP1SLC1A3SLC1A2 | |
| SCHEMBL3613233 | 0.84 | METAP2 (0.43) | CPB2METAP2METAP1SLC1A3SLC1A2 | |
| SCHEMBL3603322 | 0.80 | LTA4H (0.43) | CPB2METAP2METAP1CTSKLTA4H | |
| SCHEMBL3603318 | 0.80 | LTA4H (0.43) | CPB2METAP2METAP1CTSKLTA4H | |
| SCHEMBL969489 | 0.79 | REN (0.40) | CPB2METAP2METAP1CTSSCTSK | |
| SCHEMBL3616178 | 0.78 | METAP2 (0.46) | CPB2METAP2METAP1CTSKLTA4H | |
| SCHEMBL3616181 | 0.78 | METAP2 (0.46) | CPB2METAP2METAP1CTSKLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | DNPEP, PEPD, ACE | CPB2 45/4885METAP2 44/4885METAP1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.